To investigate the efficacy of topical cyclosporine A 0.5% as a substitute for corticosteroids in the management of therapeutic keratoplasties for mycotic keratitis.
Prospective, nonrandomized interventional case series. Three patients with culture-proven mycotic keratitis underwent therapeutic keratoplasties. All were treated with topical cyclosporine A 0.5% postoperatively as a primary or an adjunctive therapy for prevention of allograft rejection. The patients were followed up from 15 to 42 months for maintenance of graft clarity and best-corrected visual acuity.
Two of three patients maintained clear grafts while using topical cyclosporine A 0.5% twice daily with best-corrected visual acuity of 20/40 and 20/50. One patient developed an opacified graft secondary to preexisting ocular surface disease.
Topical cyclosporine A 0.5% may be a useful adjunct in the management of therapeutic keratoplasties for mycotic keratitis.
From the Department of Ophthalmology, North Shore University Hospital, Long Island Jewish Medical Center, Great Neck, New York, U.S.A.
Submitted April 24, 2001.
Revision received September 27, 2001.
Accepted October 3, 2001.
Address correspondence and reprint requests to Dr. H.D. Perry, 2000 North Village Avenue, Suite 402, Rockville Center, NY 11561, U.S.A.